India does not need to win the race for the smallest transistor. Instead, it can replicate its generic-medicine success by becoming the world’s generic chip factory for essential, high-volume semiconductors.
New Delhi (ABC Live): India did not become the “pharmacy of the world” by discovering the most new drugs. Instead, it succeeded by mastering scale, discipline, cost control, quality, and trust in making high-volume generic medicines. Today, nearly one out of every three generic medicines used worldwide is made in India.
Similarly, the same approach can now apply to semiconductors — the chips that power the digital economy.
Rather than chasing ever-smaller transistors, India can instead aim to become the most reliable producer of essential, high-volume chips. In other words, these chips are the technology version of generic medicines. Consequently, they quietly support phones, cars, factories, and power systems around the world.
Strategic Context & Policy Framework
Over the past few years, India’s semiconductor policy has moved from announcements to real action. In particular, under India Semiconductor Mission 2.0, the focus has shifted to backend chip assembly, mature-node chip production, and tight links with electronics factories.
Moreover, ABC Live has explained how this policy reset is designed to create fast industrial impact:
➡️ https://abclive.in/2026/02/01/india-semiconductor-mission-2-0/
At the same time, government press releases confirm financial support and policy backing:
➡️ https://www.pib.gov.in/PressReleasePage.aspx?PRID=2231381®=3&lang=1
➡️ https://www.pib.gov.in/PressReleasePage.aspx?PRID=2231345®=3&lang=1
As a result, investments and factory plans are now moving forward across India.
What “Generic Semiconductors” Mean
In simple terms, generic semiconductors are chips that:
-
Use mature or specialty nodes (28nm–130nm)
-
Are produced in very large numbers
-
Focus on low cost and long life
-
Are used in everyday devices
For example, common categories include PMICs, analog chips, automotive MCUs, display drivers, sensors, MOSFETs, IGBTs, connectivity chips, and memory packages.
Therefore, these chips are everywhere. In short, they are simple, stable, and made in huge volumes.
The Pharma Model and the Chip Model
In pharma, India built strength in three steps:
APIs → Formulations → Finished medicines
Likewise, in chips:
Wafers → Packaging & Testing → Electronics products
| Pharma Stage | Chip Stage | India’s Plan |
|---|---|---|
| API plants | Chip fabs | Build 1–2 strong fabs |
| Formulation plants | OSAT / ATMP | Expand quickly |
| Contract manufacturing | EMS | Link with device makers |
| Quality regulators | Testing labs | Build trust |
As a result, India can compete without leading the smallest chip sizes.
Why Backend Comes First
First, backend plants cost less.
Second, they start faster (18–30 months).
Third, they create jobs quickly.
Finally, they bring export income sooner.
Therefore, policy should give higher support to backend plants, create ready-to-use chip parks, and keep approvals simple.
Selective Fab Strategy
However, India does not need many fabs.
Instead, build one or two strong clusters and focus on power, analog, automotive, and industrial chips.
As a result, risk falls, and success chances rise.
Lock Product Niches
Equally important, India should target chips with big markets, long life cycles, and stable demand.
| Chip Type | Used In |
|---|---|
| PMICs | EVs, phones |
| Power MOSFETs | Solar, EVs |
| Automotive MCUs | Vehicles |
| Display drivers | TVs, phones |
| Sensors | Cars, factories |
| Connectivity ICs | IoT |
| Memory packages | PCs, servers |
Create Steady Domestic Demand
Just as public hospitals bought generic medicines, the government can support chip demand.
Key sectors include defence, railways, power grids, EV charging, and telecom.
Consequently, long-term purchase contracts can reduce business risk.
Build Trust Through Quality
Meanwhile, India must build chip testing labs, failure analysis centres, and car-grade certification labs.
As a result, global buyers will trust Indian chips.
Scale Skilling Pipelines
Furthermore, chip making needs engineers, technicians, operators, and designers.
Therefore, India must expand chip-focused colleges, training centres, and internships.
Encourage Fabless “Generic Chip Designers”
At the same time, small firms should design power circuits, sensor chips, and connectivity chips.
Accordingly, design grants and low-cost tools are critical.
Accept Practical Limits
Importantly, India will not lead the smallest chip sizes soon.
However, that is fine.
Just as India does not invent most new drugs but still dominates generics, it can lead in the chip manufacturing scale.
How Tata, HCL–Foxconn, and Micron Fit into This Model
India’s generic semiconductor stack already has three strong anchors:
- Tata Group
- HCL Group – Foxconn
- Micron Technology
Together, they mirror the pharma structure:
APIs → Formulations → Finished Medicines
Wafers → Packaging & Testing → Electronics Products
Comparison Table
| Parameter | Tata Group | HCL–Foxconn | Micron Technology |
|---|---|---|---|
| Main role | Fab + OSAT | OSAT | Memory ATMP |
| Focus | Mature & specialty wafers | Multi-product packaging | DRAM & NAND packaging |
| Output type | Generic chips | Generic chips | Commodity memory |
| Risk level | Higher | Medium | Medium |
| Strategic value | Wafer supply | Chip finishing | Memory backbone |
Therefore, Tata acts as the API producer, while HCL–Foxconn and Micron act as formulation plants.
What Success Looks Like by 2035
| Goal | Target |
|---|---|
| Global share (generic chips) | 5–10% |
| Chip exports | $40–50B+ |
| Global OSAT rank | Top 5 |
| Memory packaging rank | Top 3 |
| Electronics trade balance | Positive |
Bottom Line
Therefore, India can replicate its generic medicine success in semiconductors by focusing on:
Scale, reliability, cost, and mature technology.
In conclusion, just as generic medicines support global healthcare, generic and specialty semiconductors can support the global digital economy, with India as a major supplier
